AG
BMRN icon

Advisor Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advisor Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3
Closed -$1K – 4503
2016
Q3 		$1K Buy
+3
New +$282 ﹤0.01% 4275

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Advisor Group's BMRN Position: Q4 2019 in Review

Advisor Group increased its BioMarin Pharmaceuticals (BMRN) stake by 4.9% in Q4 2019, buying an estimated $33.7K and bringing the position to 9,565 shares worth $808K. The position accounts for 0.01% of the portfolio, ranked #1346.

Advisor Group first reported a position in BMRN in Q2 2016 and has held it in 15 quarters since. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Advisor Group held 9,565 shares of BioMarin Pharmaceuticals worth $808K as of Q4 2019.
  • Advisor Group bought 446 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $33.7K.
  • BioMarin Pharmaceuticals made up 0.01% of Advisor Group's portfolio in Q4 2019, its #1346 holding.
  • Advisor Group first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.